查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1523275

恐惧症市场报告：2030 年趋势、预测与竞争分析

Agoraphobia Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

恐惧症的趋势与预测

预计到 2030 年，全球恐惧症市场规模将达到 15 亿美元，2024 年至 2030 年复合年增长率为 6.3%。这个市场的主要驱动力是恐慌和焦虑症发病率的上升、对以患者为中心的个人化心理健康问题治疗的需求不断增长，以及虚拟实境暴露疗法的接受度不断提高。全球恐惧症市场的未来充满希望，医院、诊所和学术机构市场充满机会。

按细分领域分類的恐惧症

这项研究包括按药物治疗、疗法、最终用途和地区对全球恐惧症的预测。

恐惧症市场洞察

由于 SSRI 有助于缓解与恐惧症相关的焦虑，并帮助患者更好地应对压力情况，因此 Lucintel 预计选择性血清素再回收抑制剂将在预测期内成为市场上最大的部分，我们预测这种情况将持续下去。

医院仍然是该市场中最大的部分。

由于该地区人口恐惧症频率不断增加，在预测期内，北美仍将是最大的地区。

常问问题

Q1.市场规模为：

A1. 到 2030 年，全球恐惧症市场预计将达到 15 亿美元。

Q2.市场成长预测是多少：

A2. 2024 年至 2030 年，全球恐惧症市场预计将以 6.3% 的复合年增长率成长。

Q3.影响市场成长的主要驱动因素是：

A3. 这个市场的主要驱动力是恐慌和焦虑症发病率的上升、对以患者为中心的心理健康问题个性化治疗的需求不断增长以及对虚拟现实暴露疗法的接受度不断提高。

Q4.市场的主要细分市场是：

A4. 全球恐惧症市场前景广阔，医院、诊所和学术机构市场充满机会。

Q5.市场的主要企业是：

A5.主要恐惧症相关企业如下：

  • Eli Lilly and Company
  • GlaxoSmithKline
  • Pfizer
  • AstraZeneca
  • Bristol-Myers Squibb Company
  • Johnson & Johnson
  • Lundbeck
  • Takeda Pharmaceutical
  • Mylan Pharmaceuticals
  • Apotex

Q6.未来最大的细分市场是什么？

A6.Lucintel 预计选择性血清素再回收抑制剂在预测期内仍将是其最大的细分市场。这是因为 SSRI 可以帮助缓解与恐惧症相关的焦虑，并帮助患者更好地应对压力情况。

Q7. 未来五年预计哪些地区的市场成长最大？

A7. 由于该地区人口广场恐惧症的发生率不断增加，北美在预测期内仍然是最大的地区。

Q8. 可以客製化报告吗？

A8. 是的，Lucintel 提供 10% 的客製化服务，无需额外付费。

目录

第一章执行摘要

第二章全球恐惧症市场：市场动态

  • 简介、背景、分类
  • 供应链
  • 产业驱动因素与挑战

第三章 2018-2030年市场趋势及预测分析

  • 宏观经济趋势（2018-2023）与预测（2024-2030）
  • 全球恐惧症市场趋势（2018-2023）与预测（2024-2030）
  • 按药物治疗分類的全球恐惧症市场
    • 选择性血清素再回收抑制剂
    • 去甲肾上腺素再回收抑制剂
    • 抗焦虑药
    • 其他的
  • 按治疗分類的全球恐惧症市场
    • 心理治疗
    • 认知行为疗法
    • 暴露疗法
    • 其他的
  • 以最终用途分類的全球恐惧症市场
    • 医院
    • 诊所
    • 学术机构
    • 其他的

第四章 2018-2030年区域市场趋势及预测分析

  • 按地区分類的全球恐惧症市场
  • 北美恐惧症市场
  • 欧洲恐惧症市场
  • 亚太地区恐惧症市场
  • 其他区域恐惧症市场

第五章 竞争分析

  • 产品系列分析
  • 营运整合
  • 波特五力分析

第六章 成长机会与策略分析

  • 成长机会分析
  • 全球恐惧症市场的新趋势
  • 战略分析
    • 新产品开发
    • 全球恐惧症市场的容量扩张
    • 全球恐惧症市场的合併、收购与合资企业
    • 认证和许可

第七章主要企业概况

  • Eli Lilly and Company
  • GlaxoSmithKline
  • Pfizer
  • AstraZeneca
  • Bristol-Myers Squibb Company
  • Johnson & Johnson
  • Lundbeck
  • Takeda Pharmaceutical
  • Mylan Pharmaceuticals
  • Apotex
简介目录

Agoraphobia Trends and Forecast

The future of the global agoraphobia market looks promising with opportunities in the hospital, clinic, and academic markets. The global agoraphobia market is expected to reach an estimated $1.5 billion by 2030 with a CAGR of 6.3% from 2024 to 2030. The major drivers for this market are rising rates of panic and anxiety disorders, growing need for patient-centered, individualized treatment for mental health issues, as well as, increasing acceptance of virtual reality exposure treatment.

A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.

Agoraphobia by Segment

The study includes a forecast for the global agoraphobia by drug treatment, therapy, end use, and region.

Agoraphobia Market by Drug Treatment [Shipment Analysis by Value from 2018 to 2030]:

  • Selective Serotonin Reuptake Inhibitor
  • Norepinephrine Reuptake Inhibitor
  • Anti-Anxiety Medication
  • Others

Agoraphobia Market by Therapy [Shipment Analysis by Value from 2018 to 2030]:

  • Psychotherapy
  • Cognitive Behavioral Therapy
  • Exposure Therapy
  • Others

Agoraphobia Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Hospital
  • Clinic
  • Academic
  • Others

Agoraphobia Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Agoraphobia Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies agoraphobia companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the agoraphobia companies profiled in this report include-

  • Eli Lilly and Company
  • GlaxoSmithKline
  • Pfizer
  • AstraZeneca
  • Bristol-Myers Squibb Company
  • Johnson & Johnson
  • Lundbeck
  • Takeda Pharmaceutical
  • Mylan Pharmaceuticals
  • Apotex

Agoraphobia Market Insights

Lucintel forecasts that selective serotonin reuptake inhibitor will remain the largest segment over the forecast period because SSRIs is useful in relieving anxiety associated with agoraphobia, assisting patients in better managing stressful circumstances.

Within this market, hospital will remain the largest segment.

North America will remain the largest region over the forecast period due to increase in the frequency of agoraphobia among the region's population.

Features of the Global Agoraphobia Market

Market Size Estimates: Agoraphobia market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Agoraphobia market size by drug treatment, therapy, end use, and region in terms of value ($B).

Regional Analysis: Agoraphobia market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different drug treatment, therapy, end use, and regions for the agoraphobia market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the agoraphobia market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the agoraphobia market size?

Answer: The global agoraphobia market is expected to reach an estimated $1.5 billion by 2030.

Q2. What is the growth forecast for agoraphobia market?

Answer: The global agoraphobia market is expected to grow with a CAGR of 6.3% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the agoraphobia market?

Answer: The major drivers for this market are rising rates of panic and anxiety disorders, growing need for patient-centered, individualized treatment for mental health issues, as well as, increasing acceptance of virtual reality exposure treatment.

Q4. What are the major segments for agoraphobia market?

Answer: The future of the global agoraphobia market looks promising with opportunities in the hospital, clinic, and academic markets.

Q5. Who are the key agoraphobia market companies?

Answer: Some of the key agoraphobia companies are as follows:

  • Eli Lilly and Company
  • GlaxoSmithKline
  • Pfizer
  • AstraZeneca
  • Bristol-Myers Squibb Company
  • Johnson & Johnson
  • Lundbeck
  • Takeda Pharmaceutical
  • Mylan Pharmaceuticals
  • Apotex

Q6. Which agoraphobia market segment will be the largest in future?

Answer: Lucintel forecasts that selective serotonin reuptake inhibitor will remain the largest segment over the forecast period because SSRIs is useful in relieving anxiety associated with agoraphobia, assisting patients in better managing stressful circumstances.

Q7. In agoraphobia market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to increase in the frequency of agoraphobia among the region's population.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the agoraphobia market by drug treatment (selective serotonin reuptake inhibitor, norepinephrine reuptake inhibitor, anti-anxiety medication, and others), therapy (psychotherapy, cognitive behavioral therapy, exposure therapy, and others), end use (hospital, clinic, academic, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Agoraphobia Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Agoraphobia Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Agoraphobia Market by Drug Treatment
    • 3.3.1: Selective Serotonin Reuptake Inhibitor
    • 3.3.2: Norepinephrine Reuptake Inhibitor
    • 3.3.3: Anti-Anxiety Medication
    • 3.3.4: Others
  • 3.4: Global Agoraphobia Market by Therapy
    • 3.4.1: Psychotherapy
    • 3.4.2: Cognitive Behavioral Therapy
    • 3.4.3: Exposure Therapy
    • 3.4.4: Others
  • 3.5: Global Agoraphobia Market by End Use
    • 3.5.1: Hospital
    • 3.5.2: Clinic
    • 3.5.3: Academic
    • 3.5.4: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Agoraphobia Market by Region
  • 4.2: North American Agoraphobia Market
    • 4.2.1: North American Agoraphobia Market by Drug Treatment: Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication, and Others
    • 4.2.2: North American Agoraphobia Market by End Use: Hospital, Clinic, Academic, and Others
  • 4.3: European Agoraphobia Market
    • 4.3.1: European Agoraphobia Market by Drug Treatment: Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication, and Others
    • 4.3.2: European Agoraphobia Market by End Use: Hospital, Clinic, Academic, and Others
  • 4.4: APAC Agoraphobia Market
    • 4.4.1: APAC Agoraphobia Market by Drug Treatment: Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication, and Others
    • 4.4.2: APAC Agoraphobia Market by End Use: Hospital, Clinic, Academic, and Others
  • 4.5: ROW Agoraphobia Market
    • 4.5.1: ROW Agoraphobia Market by Drug Treatment: Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication, and Others
    • 4.5.2: ROW Agoraphobia Market by End Use: Hospital, Clinic, Academic, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Agoraphobia Market by Drug Treatment
    • 6.1.2: Growth Opportunities for the Global Agoraphobia Market by Therapy
    • 6.1.3: Growth Opportunities for the Global Agoraphobia Market by End Use
    • 6.1.4: Growth Opportunities for the Global Agoraphobia Market by Region
  • 6.2: Emerging Trends in the Global Agoraphobia Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Agoraphobia Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Agoraphobia Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Eli Lilly and Company
  • 7.2: GlaxoSmithKline
  • 7.3: Pfizer
  • 7.4: AstraZeneca
  • 7.5: Bristol-Myers Squibb Company
  • 7.6: Johnson & Johnson
  • 7.7: Lundbeck
  • 7.8: Takeda Pharmaceutical
  • 7.9: Mylan Pharmaceuticals
  • 7.10: Apotex